Intensity Therapeutics Inc. (INTS)
(Delayed Data from NSDQ)
$0.29 USD
+0.03 (10.32%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.28 -0.01 (-4.44%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INTS 0.29 +0.03(10.32%)
Will INTS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INTS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INTS
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
INTS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for INTS
Intensity Therapeutics raises $6.6M via at-the-market offering
Intensity Therapeutics (INTS) Raises $6.6M Through At-the-Market Offering
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales ...
Intensity Therapeutics raises $6.6M from ATM stock sales in July
Intensity Therapeutics (INTS) Receives Buy Rating Amid Clinical Shift